Generex Biotech receives new patents for buccal applications

June 2009
Medical Device Daily;6/15/2009, Vol. 13 Issue 113, p10
The article reports on the five patents in Canada, Australia, New Zealand, Brazil and Lebanon received by Generex Biotechnology. Additional protection for Generex's proprietary compositions and methodologies for delivering pharmaceuticals in buccal applications is provided by the patents. It is noted that the company now holds an aggregate of 116 patent applications pending in several jurisdictions worldwide.


Related Articles

  • GENEREX AWARDED PATENTS IN NORTH AND SOUTH AMERICA.  // Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p7 

    The article announces that Generex Biotechnology Corp. has received patents in Canada and Argentina. The Canadian Intellectual Property Office has granted Generex a patent that contains process, formulation and use claims to a mixed micellar pharmaceutical formulation for buccal administration,...

  • GENEREX GETS CHINA PATENT FOR II-KEY PETIDE VACCINE.  // Worldwide Biotech;Apr2010, Vol. 22 Issue 4, p1 

    The article reports that Generex Biotechnology Corp. has received a patent for its Ii-Key peptide vaccine technology in China. The company has begun discussions for potential joint venture/licensing partnerships with pharmaceutical companies for its peptide cancer vaccine technology platform....

  • GENEREX AWARDED TWO NEW PATENTS FOR BUCCAL DRUG DELIVERY.  // Biotech Business;Jul2010, Vol. 23 Issue 7, p7 

    The article reports that Generex Biotechnology Corporation was awarded patents in Japan and Ukraine. According to Rose C. Perri, the company's chief operating officer, each patent issuance suggests the inventiveness of the company's buccal drug delivery platform technologies. Generex is based in...

  • GENEREX BIOTECHNOLOGY AWARDED NEW DRUG DELIVERY PATENT.  // Worldwide Biotech;Dec2008, Vol. 20 Issue 12, p1 

    The article reports on a drug delivery patent received by Generex Biotechnology Corp., a leading provider of drug delivery for metabolic diseases through the inner lining of the mouth, in Australia. A patent titled Micellar Pharmaceutical Compositions for Buccal and Pulmonary Application has...

  • European patents for Generex.  // European Pharmaceutical Executive;Sep2007, p9 

    The article reports that the European Patent Office has granted the fourth European patent of Generex Biotechnology Corp. entitled "Proteinic Drug Delivery System Using Membrane Mimetics." The patent includes formulation and process claims for liposome pharmaceutical formulation, which was...

  • Generex Receives Patent for Buccal Delivery of Insulin.  // BioPharm International;Dec2006, Vol. 19 Issue 12, p12 

    The article reports on the acquisition of an Australian patent by Generex Biotechnology Corp. for its micellar system that delivers macromolecules through buccal lining. Excipients will form a spherical micelle of surfactant molecules which will shield the protein from digestion by buccal...

  • Global Report.  // Pharmaceutical Representative;Mar2010, Vol. 40 Issue 3, p10 

    The article offers updates related to drug licenses and patents in Great Britain and Europe.

  • Other News To Note.  // BioWorld Today;7/16/2010, Vol. 21 Issue 136, p3 

    This section offers news briefs in the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) has grant continued listing to Generex Biotechnology Corp. on an interim basis. A patent infringement case has been filed by Gilead Sciences Inc. against Lupin Ltd. for its Ranexa patents....

  • Spray On, Insulin Users, Spray On.  // Diabetes Health;Feb/Mar2007, Vol. 16 Issue 1, p29 

    The article announces that Oral-lyn, an insulin spray developed by Generex Biotechnology Corp., has received the 2006 Technology Award for Innovation in the field of diabetic therapies from Frost and Sullivan Co.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics